Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

DPCP alone is more effective and safer for treating chronic extensive alopecia areata than combining it with anthralin.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.

Japanese patients with alopecia areata often have a higher BMI and consume more vitamin C, fruit, and retinol, which may affect their condition's development or severity.

Gut bacteria differences could help diagnose and treat alopecia areata.

Tofacitinib effectively regrows hair in alopecia universalis triggered by a virus.

Phototherapy effectively treats certain alopecia areata types, especially if started early.

Minoxidil shows promise for alopecia areata, but more research is needed before it can be recommended as a primary treatment.

Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.

Low vitamin D may increase autoimmune thyroid disease risk, but its treatment effects are unclear.

Aire mutation reduces alopecia areata, while Notch4 mutation prevents it in mice.

Vitamin D may help reduce thyroid antibodies and improve thyroid function in Hashimoto's Thyroiditis.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.

Genetic insights can lead to personalized treatments for acne, androgenetic alopecia, and alopecia areata.

The skin can independently form immune responses through special structures, offering new ways to treat skin diseases.

Alopecia Areata is linked to specific gut bacteria and metabolites, indicating a complex gut microbiome.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

JAK inhibitors show promise in effectively treating hair loss from alopecia areata.

JAK inhibitors show promise for treating various skin diseases.

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

IL-3 worsens lupus nephritis and blocking it improves kidney health.

Certain IL-18 gene variations may increase the risk of alopecia areata.

Thyroid issues can cause alopecia areata.

Chronic skin diseases and metabolic syndrome are linked by shared inflammation pathways.

Higher levels of certain proteins in the blood are linked to more severe patchy alopecia areata.

Imiquimod can cause rare skin side effects, some irreversible, and long-term follow-up is important for users.